Related Experiment Video

Updated: Aug 8, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 10, 2014

Inhibition of human immunodeficiency virus integrase by bis-catechols

R L LaFemina1, P L Graham, K LeGrow

  • 1Department of Antiviral Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.

Antimicrobial Agents and Chemotherapy
|February 1, 1995
PubMed

Insights

Beta-conidendrol inhibits human immunodeficiency virus type 1 (HIV-1) integrase in vitro, suggesting potential for new HIV therapies. However, it was not effective in preventing HIV-1 infection in cell culture.

Area of Science:

  • Biochemistry
  • Virology
  • Drug Discovery

Background:

  • Human immunodeficiency virus type 1 (HIV-1) integrase is crucial for viral replication in T-lymphoid cells.
  • Inhibiting HIV-1 integrase is a potential strategy for preventing viral spread.
  • Identifying selective chemical inhibitors of integrase is a key research objective.

Purpose of the Study:

  • To identify potential chemotherapeutic agents targeting HIV-1 integrase.
  • To evaluate beta-conidendrol and related compounds as inhibitors of HIV-1 integrase.
  • To understand the structure-activity relationship for integrase inhibition.

Main Methods:

  • In vitro assays to measure the endonucleolytic activities of HIV-1 integrase.
  • Testing beta-conidendrol and structurally related compounds for inhibitory effects.
  • Structure-activity relationship analysis of tested compounds.

Main Results:

  • Beta-conidendrol inhibited both sequence-dependent and sequence-independent endonucleolytic activities of HIV-1 integrase in vitro with an IC50 of 500 nM.
  • The bis-catechol structure was associated with inhibitory potency.
  • Beta-conidendrol showed selectivity, not inhibiting other tested endonucleases or phosphoryltransferases.
  • Beta-conidendrol did not prevent HIV-1 infection in cell culture.

Conclusions:

  • Selective inhibitors of HIV-1 integrase can be identified.
  • Beta-conidendrol demonstrates the feasibility of targeting HIV-1 integrase with small molecules.
  • Further research is needed to develop effective integrase inhibitors for HIV therapy.

More Related Videos

Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides (CHIPS)06:34

Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides (CHIPS)

Published on: June 20, 2014

Measurement of In Vitro Integration Activity of HIV-1 Preintegration Complexes10:34

Measurement of In Vitro Integration Activity of HIV-1 Preintegration Complexes

Published on: February 22, 2017

Related Concept Videos

Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...